Truist Financial Has Lowered Expectations for Globus Medical (NYSE:GMED) Stock Price

Posted by Francis Steltz on Nov 9th, 2026

Globus Medical (NYSE:GMED – Get Free Report) had its price target cut by analysts at Truist Financial from $100.00 to $90.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Truist Financial‘s price target suggests a potential upside of 27.36% from the company’s current price.

Other research analysts also recently issued reports about the company. Royal Bank Of Canada reduced their target price on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Wells Fargo & Company boosted their price target on shares of Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday. Finally, BTIG Research restated a “neutral” rating on shares of Globus Medical in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $96.08.

Get Our Latest Research Report on Globus Medical

Globus Medical Trading Down 0.5%

NYSE GMED opened at $70.67 on Monday. The stock has a market capitalization of $9.49 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.14 and a beta of 0.98. Globus Medical has a twelve month low of $70.39 and a twelve month high of $101.40. The stock has a 50-day moving average of $77.20 and a 200 day moving average of $83.18.

Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. The company had revenue of $763.72 million for the quarter, compared to the consensus estimate of $792.39 million. During the same quarter in the prior year, the business posted $1.18 earnings per share. Globus Medical’s revenue for the quarter was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts predict that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director Ann D. Rhoads sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares of the company’s stock, valued at $3,007,640. This represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James Tobin sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the transaction, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. The trade was a 66.67% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 60,000 shares of company stock worth $4,838,400. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the last quarter. Sculptor Capital LP lifted its holdings in Globus Medical by 1.9% in the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Globus Medical by 14.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock valued at $133,731,000 after purchasing an additional 225,534 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares in the last quarter. Finally, Boston Trust Walden Corp boosted its stake in Globus Medical by 4.4% during the 3rd quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock worth $123,071,000 after purchasing an additional 69,782 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.